Observational studyCNS drugs2024

Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.

Lucienne Costa-Frossard França et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.